Announcement • Feb 23
Indrayani Biotech Limited to Report Q3, 2026 Results on Feb 26, 2026 Indrayani Biotech Limited announced that they will report Q3, 2026 results on Feb 26, 2026 Reported Earnings • Dec 13
Second quarter 2026 earnings released: EPS: ₹0.09 (vs ₹0.13 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.09 (down from ₹0.13 in 2Q 2025). Revenue: ₹377.5m (up 21% from 2Q 2025). Net income: ₹9.12m (down 25% from 2Q 2025). Profit margin: 2.4% (down from 3.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Announcement • Sep 01
Indrayani Biotech Limited, Annual General Meeting, Sep 29, 2025 Indrayani Biotech Limited, Annual General Meeting, Sep 29, 2025, at 16:00 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2026 earnings released First quarter 2026 results: EPS: ₹0.03. Revenue: ₹301.6m (down 4.3% from 1Q 2025). Net income: ₹1.57m (down 82% from 1Q 2025). Profit margin: 0.5% (down from 2.7% in 1Q 2025). The decrease in margin was driven by lower revenue. Announcement • Aug 12
Indrayani Biotech Limited to Report Q1, 2026 Results on Aug 14, 2025 Indrayani Biotech Limited announced that they will report Q1, 2026 results on Aug 14, 2025 New Risk • Aug 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Market cap is less than US$10m (₹643.9m market cap, or US$7.34m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change). Reported Earnings • Jun 14
Full year 2025 earnings released: ₹1.35 loss per share (vs ₹1.64 profit in FY 2024) Full year 2025 results: ₹1.35 loss per share (down from ₹1.64 profit in FY 2024). Revenue: ₹1.33b (down 20% from FY 2024). Net loss: ₹61.1m (down 196% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹14.82, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Hospitality industry in India. Total loss to shareholders of 51% over the past three years. New Risk • Mar 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹807.8m (US$9.31m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Market cap is less than US$10m (₹807.8m market cap, or US$9.31m). Reported Earnings • Mar 01
Third quarter 2025 earnings released: EPS: ₹0.05 (vs ₹0.22 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.05 (down from ₹0.22 in 3Q 2024). Revenue: ₹173.2m (down 56% from 3Q 2024). Net income: ₹3.51m (down 68% from 3Q 2024). Profit margin: 2.0% (down from 2.8% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Feb 26
Indrayani Biotech Limited to Report Q3, 2025 Results on Feb 27, 2025 Indrayani Biotech Limited announced that they will report Q3, 2025 results on Feb 27, 2025 Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹23.87, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 36x in the Hospitality industry in India. Total loss to shareholders of 6.2% over the past three years. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹44.85, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 38x in the Hospitality industry in India. Total returns to shareholders of 65% over the past three years. Reported Earnings • Aug 16
First quarter 2025 earnings released: EPS: ₹0.10 (vs ₹0.09 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.10 (up from ₹0.09 loss in 1Q 2024). Revenue: ₹315.7m (down 25% from 1Q 2024). Net income: ₹8.50m (up ₹13.0m from 1Q 2024). Profit margin: 2.7% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth. Announcement • Jul 29
Indrayani Biotech Limited, Annual General Meeting, Aug 22, 2024 Indrayani Biotech Limited, Annual General Meeting, Aug 22, 2024, at 15:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹55.36, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 36x in the Hospitality industry in India. Total returns to shareholders of 448% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹1.40 (vs ₹2.55 in FY 2023) Full year 2024 results: EPS: ₹1.40. Revenue: ₹1.67b (up 2.8% from FY 2023). Net income: ₹104.2m (up 19% from FY 2023). Profit margin: 6.2% (up from 5.4% in FY 2023). The increase in margin was driven by higher revenue. Buy Or Sell Opportunity • May 29
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to ₹48.96. The fair value is estimated to be ₹63.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • May 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 31% to ₹51.56. The fair value is estimated to be ₹64.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹59.72, the stock trades at a trailing P/E ratio of 60.5x. Average trailing P/E is 41x in the Hospitality industry in India. Total returns to shareholders of 823% over the past three years. Buy Or Sell Opportunity • Mar 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to ₹50.81. The fair value is estimated to be ₹64.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% over the last 3 years. Meanwhile, the company has become profitable. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Bokara Nagarajan Priyadharshini was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jan 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (167% net debt to equity). Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₹3.39b market cap, or US$40.8m). Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹74.50, the stock trades at a trailing P/E ratio of 49.5x. Average trailing P/E is 32x in the Hospitality industry in India. Total returns to shareholders of 907% over the past three years. Announcement • Jan 10
Indrayani Biotech Limited Announces Company Secretary & Compliance Officer Changes The Board of Directors of Indrayani Biotech Limited took note of the resignation of Mr. Rajesh Kumar Sundarray (ACS membership number: A66744) from the office of Company Secretary & Compliance Officer with effect from closing hours on January 10, 2024 due to personal reasons, and has appointed Mr. V Santhanakrishnan (ACS membership number: A54146) for the position of Company Secretary & Compliance Officer with effect from January 11, 2024. Mr. V.Santhanakrishnan is an Associate member of the Institute of Company Secretaries of India (Membership no. A54146), having 7 years of experience in secretarial functions. He has done his graduation from RDB College of Arts & Science, Papanasam. Reported Earnings • Nov 17
Second quarter 2024 earnings released: EPS: ₹0.89 (vs ₹1.54 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.89. Revenue: ₹405.3m (down 3.6% from 2Q 2023). Net income: ₹55.4m (up 5.4% from 2Q 2023). Profit margin: 14% (up from 13% in 2Q 2023). The increase in margin was driven by lower expenses. New Risk • Nov 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₹2.57b market cap, or US$30.9m). Reported Earnings • Aug 13
First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.52 profit in 1Q 2023) First quarter 2024 results: ₹0.09 loss per share (down from ₹0.52 profit in 1Q 2023). Revenue: ₹423.1m (up 65% from 1Q 2023). Net loss: ₹4.46m (down 125% from profit in 1Q 2023). Announcement • Aug 06
Indrayani Biotech Limited to Report Q1, 2024 Results on Aug 11, 2023 Indrayani Biotech Limited announced that they will report Q1, 2024 results on Aug 11, 2023 New Risk • Jun 25
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.5x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.85b market cap, or US$22.6m). New Risk • Jun 19
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks High level of debt (123% net debt to equity). Market cap is less than US$100m (₹1.98b market cap, or US$24.1m). Reported Earnings • Jun 15
Full year 2023 earnings released: EPS: ₹5.95 (vs ₹1.30 in FY 2022) Full year 2023 results: EPS: ₹5.95 (up from ₹1.30 in FY 2022). Revenue: ₹1.67b (up 172% from FY 2022). Net income: ₹119.3m (up 169% from FY 2022). Profit margin: 7.1% (down from 7.2% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 23
Indrayani Biotech Limited to Report Q4, 2023 Results on May 30, 2023 Indrayani Biotech Limited announced that they will report Q4, 2023 results on May 30, 2023 Announcement • May 12
Indrayani Biotech Limited Announces Executive Changes Indrayani Biotech Limited informed that Ms. Vennila Vijayaragavan has resigned from the office of Company Secretary due to her inability to continue after Maternity leave, with effect from 10 May 2023 after the business hours of the company. Consequently, the office of Compliance officer of the Company, Ms. Mamtha Madesh appointed on behalf of the Company Secretary during the tenure of her absence on Maternity leave shall also be ceased with effect from the resignation of Company Secretary 10 May 2023. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹69.49, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 20x in the Electrical industry in India. Total returns to shareholders of 732% over the past three years. Reported Earnings • Feb 17
Third quarter 2023 earnings released: EPS: ₹0.72 (vs ₹0.33 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.72 (up from ₹0.33 in 3Q 2022). Revenue: ₹460.0m (up 202% from 3Q 2022). Net income: ₹34.4m (up 201% from 3Q 2022). Profit margin: 7.5% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 111% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 15
Indrayani Biotech Limited (BSE:526445) acquired 51% stake in Matrix Boilers Private Limited for INR2.8 million. Indrayani Biotech Limited (BSE:526445) acquired 51% stake in Matrix Boilers Private Limited for INR2.8 million on November 14, 2022.Indrayani Biotech Limited (BSE:526445) completed the acquisition of 51% stake in Matrix Boilers Private Limited for INR2.8 million on November 14, 2022. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 19% share price gain to ₹95.80, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 23x in the Electrical industry in India. Total returns to shareholders of 1,816% over the past three years. Announcement • Nov 06
Indrayani Biotech Limited to Report Q2, 2023 Results on Nov 14, 2022 Indrayani Biotech Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹93.70, the stock trades at a trailing P/E ratio of 57.4x. Average trailing P/E is 22x in the Electrical industry in India. Total returns to shareholders of 1,774% over the past three years. Announcement • Sep 08
Indrayani Biotech Limited, Annual General Meeting, Sep 30, 2022 Indrayani Biotech Limited, Annual General Meeting, Sep 30, 2022, at 12:30 Indian Standard Time. Agenda: To consider and approve the Audited Financial Statements (standalone and consolidated Financial Statements) of the Company for the Financial year ended March 31, 2022 together with the Reports of the Board of Directors and the Statutory Auditors thereon, including Annexures thereto; to consider and approve the appointment of a director in place of Mrs. Lakshmiprabha Kasiraman who retires by rotation and being eligible offers herself for re-appointment as Non-Executive Director of the Company; and to consider other matters. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improved over the past week After last week's 19% share price gain to ₹68.70, the stock trades at a trailing P/E ratio of 42.1x. Average trailing P/E is 21x in the Electrical industry in India. Total returns to shareholders of 1,346% over the past three years. Announcement • Aug 07
Indrayani Biotech Limited to Report Q1, 2023 Results on Aug 13, 2022 Indrayani Biotech Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 17% share price gain to ₹57.55, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 20x in the Electrical industry in India. Total returns to shareholders of 1,074% over the past three years. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improved over the past week After last week's 17% share price gain to ₹40.80, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 21x in the Electrical industry in India. Total returns to shareholders of 640% over the past three years. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improved over the past week After last week's 18% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 19x in the Electrical industry in India. Total returns to shareholders of 809% over the past three years. Announcement • May 25
Indrayani Biotech Limited to Report Q4, 2022 Results on May 30, 2022 Indrayani Biotech Limited announced that they will report Q4, 2022 results on May 30, 2022 Announcement • May 10
Indrayani Biotech Limited announced that it has received INR 235.16798 million in funding On May 9, 2022, the company has issued 6,300,000 preference shares for gross proceeds of INR 148,050,000 and 10,59,064 warrants for proceeds of INR 7,942,980 for aggregate gross proceeds of INR 155,992,980 in its second tranche. The tranche included participation from Malarvannan Subashini for 1,059,064 warrants, Sanjay Ravindra Mehta, Reena Amit Lapasia, Khyati Nilesh Parekh, Divyesh Shashikant Kapadia, Jayaseelan S, Geetha Kannan, Sabitha, Subhulakshmi S for 6,300,000 preference shares. Announcement • May 08
Indrayani Biotech Limited Approves Constitution the Allotment Committee The Board of Directors of Indrayani Biotech Limited in its meeting held on May 06, 2022 approved constituted the Allotment Committee consisting of: Mr. Nangavaram Mahadevan Ranganathan (Independent Director and Chairperson of the company), Mr. Singarababu Indirakumar (Whole-time Director of the Company), Mr. G. Swaminathan (Whole-time Director of the Company) and Mrs. Bokara Nagarajan Padmaja Priyadarshini (Independent Director of the Company). Announcement • Mar 29
Indrayani Biotech Limited Announces Management Changes Indrayani Biotech Limited announced that the board of directors took note of the resignation of Ms. R. Charu Latha from the office of Company Secretary & Compliance Officer with effect from 28 March 2022 and has appointed Mrs. Vennila Vijayaragavan for the position of Company Secretary & Compliance Officer with effect from 28 March 2022. Announcement • Feb 16
Indrayani Biotech Limited Appoints Krishnamurthi Ravichandran as the Secretarial Auditor of the Company for the Financial Year 2021-22 Indrayani Biotech Limited appointed Krishnamurthi Ravichandran as the Secretarial auditor of the Company for the Financial Year 2021-22 pursuant to section 204 and Rule 8 of the Companies (Meetings of Board and its powers) Rules, 2014 of Companies Act, 2013 at the board meeting held on February 14, 2022. Announcement • Feb 08
Indrayani Biotech Limited to Report Q3, 2022 Results on Feb 14, 2022 Indrayani Biotech Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Announcement • Nov 22
Indrayani Biotech Limited to Report Fiscal Year 2020 Results on Nov 28, 2020 Indrayani Biotech Limited announced that they will report fiscal year 2020 results on Nov 28, 2020 Announcement • Aug 22
Indrayani Biotech Limited to Report Q1, 2021 Results on Aug 29, 2020 Indrayani Biotech Limited announced that they will report Q1, 2021 results on Aug 29, 2020 